|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival显示文摘BACKGROUND: In a multidisciplinary conference patients with advanced non-resectable hepatocellular carcinoma (HCC) were stratified according to their clinical status and tumor extent to different regional modalities or to best supportive care. The present study evaluated all patients who were stratified to repeated transarterial chemoembolization (TACE) from 1999 until 2003 in terms of tumor response, toxicity, and survival. A moderate embolizing approach was chosen using a combination of degradable starch microspheres (DSM) and iodized oil (Lipiodol) in order to combine anti-tumoral efficiency and low toxicity. METHODS: Fourty-seven patients were followed up prospectively. TACE treatment consisted of cisplatin (50 mg/m2), doxorubicin (50 mg/m2), 450-900 mg DSM, and 5-30 ml Lipiodol. DSM and Lipiodol were administered according to tumor vascularization. Patient characteristics,toxicity, and complications were outlined. In multivariate regression analyses of pre-treatment variables from a prospective database, predictors for tumor response and survival after TACE were determined. RESULTS: 112 TACE courses were performed (2.4±1.5 courses per patient). Mean maximum tumor size was 75 (± 43) mm, in 68% there was bilobar disease. Best response to TACE treatment was: progressive disease (PD) 9%, stable disease (SD) 55%, partial remission (PR) 36%, and complete remission (CR) 0%. Multivariate regression analyses identified tumor size ≤75 mm, tumor number ≤5, and tumor hypervascularization as predictors for PR. The overall 1-, 2-, and 3-year-survival rates were 75%, 59%, and 41%, respectively, and the median survival was 26 months. Low α-fetoprotein levels (<400 ng/ml) (Odds ratio=3.3) and PR as best response to TACE (Odds ratio=6.7) were significantly associated with long term survival (>30 months, R2=36%). Grade 3 toxicity occurred in 7.1% (n=8), and grade 4 toxicity in 3.6% (n=4) of all courses in terms of reversible leukopenia and thrombocytopenia. The incidence of major complications was 5.4% (n=6). All complications were managed conservatively. The mortality within 6 weeks after TACE was 2.1% (one patient). CONCLUSIONS: DSM and Lipiodol were combined successfully in the palliative TACE treatment of advanced HCC resulting in high rates of tumor response and survival at limited toxicity. Favourable tumor response was associated with tumor extent and vascularization. TACE using DSM and Lipiodol can be considered a suitable palliative measure in patients who might not tolerate long acting embolizing agents. | Timm D Kirchhoff Joerg S Bleck Arne Dettmer Ajay Chavan Herbert Rosenthal Sonja Merkesdal Bernd Frericks Lars Zender Nisar P Malek Tim F Greten Stefan Kubicka Michael P Manns Michael Galanski | 2007 | Hepatobiliary & Pancreatic Diseases International2007，6，3： | 15 |
| 2 | Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma显示文摘瞄准:为病人评估经皮的乙醇注射(PEI ) 的治疗效果与先进, non-resectable HCC 与 transarterial chemoembolisation 的联合相比(不作声) 并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。方法:在学习时期期间接受了 PEI 治疗的所有病人根据物理地位和肿瘤程度被包括并且成层到下列治疗形式之一:联合不作声并且重复单个会议的 PEI,独自重复了单个会议的 PEI,重复不作声独自一个,或最好的支持的照顾。包括Okuda分类,门静脉血栓的存在,腹水的存在,肿瘤的数字,最大的肿瘤直径,和假胆硷酯酶( CHE )的临床的参数的预示的价值,以及孩子呸上演, alpha-fetoprotein (法新社),发烧,复杂并发症的发生在这些组之间被估计并且比较。幸存用 Kaplan-Meier 被决定,多,变量回归分析。结果:所有病人的 1 年、 3 年的幸存是 73% 和 47% 。在亚群分析,联合不作声, PEI (1 ) 与更长的幸存被联系(1- , 3- , 5 年的幸存:90% , 52% ,和 43%) 与 PEI 治疗相比独自一个(2 )(1- , 3- , 5 年的幸存:65% , 50% ,和 37%) 。(3 ) 在起始的层化以后的第二等的 PEI 产出可比较的结果不作声(1- , 3- , 5 年的幸存:91% , 40% ,和 30%) 当在到最好的支持的照顾(4 ) 的层化以后的 PEI 与减少的幸存被联系时(1- , 3- , 5 年的幸存:50% , 23% , 12%) 。除了选择治疗形式,为更好的幸存的预言者是肿瘤数字(n <
5 ) ,肿瘤尺寸(<
5 厘米) ,在 PEI 前的没有腹水,和在 PEI 以后的稳定的假胆硷酯酶(P <
0.05 ) 。在在 PEI 以后的 2 wk 以内的死亡是 2.8%(n = 3 ) 。有 24 (8.9%) 主修在包括部分肝梗塞,焦点的肝坏死,和肝脓肿的 PEI 以后的复杂并发症。所有复杂并发症能非通过手术被管理。结论:重复单个会议的 PEI 在有以可接受、可管理的复杂并发症率的先进 HCC 的病人是有效的。病人们成层到联合不作声, PEI 能比那些独自成层到重复 PEI 期望更长的幸存。而且,有在好临床的地位的大或多重的肿瘤的病人可以也从联合获利不作声并且为第二等的 PEI 的再考虑。 | Arne Dettmer Timm D Kirchhoff Michael Gebel Lars Zender Nisar P Malek Bernhard Panning Ajay Chavan Herbert Rosenthal Stefan Kubicka Susanne Krusche Sonja Merkesdal Michael Galanski Michael P Manns Joerg S Bleck | 2006 | World Journal of Gastroenterology2006，12，23： | 14 |
| 3 | Transcutaneous perianal sonography:A sensitive method for the detection of perianal inflammatory lesions in Crohn's disease显示文摘AIM: Pelvic magnetic resonance imaging (MRI) and endoanalultrasound which are established imaging methods forperianal inflammatory lesions in patients with Crohn'sdisease require expensive specialized equipments andexpertise. We investigated the feasibility and sensitivity oftranscutaneous perianal ultrasound (PAUS) using regularultrasound probes in the imaging of perianal inflammatorylesions. The sonographic findings were correlated to pelvicMRI-scans.METHODS: We performed PAUS in 25 patients with Crohn'sdisease and clinical signs of perianal inflammatory disease.VCChin a median of 10 d (range 0-75) these patients underwentMRI of the pelvis. Regular convex and linear high resolutionprobes were used for PAUS. The sonographic findings werecorrelated to the MRI findings by blinded investigators.RESULTS: The sonographic investigations were welltolerated by all patients. Fistulae typically presented ashypoechoic tracks. Twenty-nine fistulae were detected in22 patients. Abscesses were detected in 7 patients andpresented as hypo- or anechoic formations. Twenty-six of29 fistulae and 6 of 7 abscesses could be confirmed byMRI. Kappa statistics showed an excellent agreement(kappa>0.83) between the two imaging methods.CONCLUSION: PAUS is a simple, painless, feasible, real-time method that can be performed without specific patientpreparation which is comparable in its sensitivity to pelvicMRI in the detection of perianal fistulae and/or abscesses.PAUS can especially be recommended as a screening toolin acute perianal disorders such as perianal abscess andfor follow-up studies of perianal inflammatory disease. | Jochen Wedemeyer Timm Kirchhoff Gernot Sellge Oliver Bachmann Joachim Lotz Michael Galanski Michael P.Manns Michael J.Gebel Jrg S.Bleck | 2004 | World Journal of Gastroenterology2004，10，19： | 8 |
| 4 | Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver显示文摘AIM: In nonresectable cholangiocellular carcinoma (CCC)therapeutic options are limited. Recently, systemic chemotherapy has shown response rates of up to 30%.Additional regional therapy of the arterially hyper vascularized hepatic tumors might represent a rational approach in an attempt to further improve response and palliation. Hence, a protocol combining transarterial chemoembolization and systemic chemotherapy was applied in patients with CCC limited to the liver.METHODS: Eight patients (6 women, 2 men, mean age 62 years) with nonresectable CCC received systemic chemotherapy (gemcitabine 1 000 mg/m2) and additional transarterial chemoembolization procedures (50 mg/m2cisplatin, 50 mg/m2 doxorubicin, up to 600 mg degradable starch microspheres). Clinical follow-up of patients, tumor markers, CT and ultrasound were performed to evaluate maximum response and toxicity.RESULTS: Both systemic and regional therapies were tolerated well; no severe toxicity (WHO Ⅲ/Ⅳ) was encountered. Nausea and fever were the most commonly observed side effects. A progressive rarefication of the intrahepatic arteries limited the maximum number of chemoembolization procedures in 4 patients. A median of 2 chemoembolization cycles (range, 1-3) and a median of 6.5 gemcitabine cycles (range, 4-11) were administered.Complete responses were not achieved. As maximum response, partial responses were achieved in 3 cases,stable diseases in 5 cases. Two patients died from progressive disease after 9 and 10 mo. Six patients are still alive. The current median survival is 12 mo (range, 9-18); the median time to tumor progression is 7 mo (range, 3-18). Seven patients suffered from tumor-related symptoms prior to therapy, 3 of these experienced a treatment-related clinical relief. In one patient the tumor became resectable under therapy and was successfully removed after 10 mo.CONCLUSION: The present results indicate that a combination of systemic gemcitabine therapy and repeated regional chemoembolizations is well tolerated and may enhance the effect of palliation in a selected group of patients with intrahepatic nonresectable CCC. | Timm Kirchhoff Lars Zender Sonja Merkesdal Bernd Frericks Nisar Malek Joerg Bleck Stefan Kubicka Stefan Baus Ajay Chavan Michael P.Manns Michael Galanski | 2005 | World Journal of Gastroenterology2005，11，8： | 3 |
| 5 | Ionic liquids for extraction of metals and metal containing compounds from communal and industrial waste water显示文摘 | Lisa Fischer Thomas Falta Gunda Koellensperger Anja Stojanovic Daniel Kogelnig Markus Galanski Regina Krachler Bernhard K. Keppler Stephan Hann | 2011 | Water Research2011，，15： | 2 |
| 6 | Pneumothorax:evaluation byultrasound preliminary results显示文摘 | Wernecke K Galanski M Peters PE | 1987 | J Thorac Imaging1987，2，2： | 1 |
| 7 | The relation between stereochemistry and biological activity of platinum(II) complexes chelated with chiral diamine ligands: an intricate problem 显示文摘 | Dufrasnel F Galanski M | 2007 | Curr Pharm Design2007，13，27： | 1 |
| 8 | Update of the preclinical situation of anticancer platinum complexes:novel design strategies and innovative analytical approaches显示文摘 | Galanski M Jakupec MA Keppier BK | 2005 | Curr Med Chem2005，12，18： | 1 |
| 9 | MDCT classification of osseous ankle and foot injuries显示文摘 | Opherk JP Rosenthal H Galanski M | 2007 | Radiologe2007，47，3： | 1 |
| 10 | Design, synthesis, physical and chemical characterisation, and biological interactions of lectin-targeted latex nanoparticles bearing Gd–DTPA chelates: an exploration of magnetic resonance molecular imaging (MRMI)显示文摘 | Irena Paschkunova-Martic Christian Kremser Klaudia Mistlberger Nadezhda Shcherbakova Hermann Dietrich Heribert Talasz Yiping Zou Beate Hugl Markus Galanski Elisabeth S?lder Kristian Pfaller Isabella H?liner Wolfgang Buchberger Bernhard Keppler Paul Debbag | 2005 | Histochemistry and Cell Biology2005，，3： | 1 |
| 11 | Tumour inhibiting platinum complexes ?state of the art and future perspectives显示文摘 | Galanski M Keppler BK | 2003 | Rev Physiol Biochem Pharmacol2003，146，： | 1 |
| 12 | Update of the preclini-cal situation of anticancer platinum complexes : novel design strat-egies and innovative analytical approaches显示文摘 | Galanski M Jakupec MA Keppler BK | 2005 | Curr Med Chem2005，12，18： | 1 |
| 13 | Spiral CT angiography of the ab domen 显示文摘 | Prokop M Schaefer-Prokop C Galanski M | 1997 | Abdom Imaging1997，22，2： | 1 |
| 14 | Sonographic diagnosis of pneumothorax 显示文摘 | Wernecke K Galanski M Peters PE | 1989 | Rofo1989，150，1： | 1 |
| 15 | Results of a federation inquiry 2005/2006: pediatric CT X-ray practice in germany显示文摘 | Galanski M Nagel HD Stamm G | 2007 | Rofo2007，179，： | 1 |
| 16 | Synthesis, cytotoxicity, and structure-activity relationships of new oxaliplatin derivatives 显示文摘 | Galanski M Yasemi A Jakupec M A | 2005 | Monatshefte fur Chemie2005，136，5： | 1 |
| 17 | Tumour-inhibiting platinum complexes-state of the art and future perspectives显示文摘 | JAKUPEC M A GALANSKI M KEPPLER B K | 2003 | Rev Physiol Biochem Pharmacol2003，146，： | 1 |
| 18 | Renal Metastases From Follicular Thyroid Cancer on SPECT/CT显示文摘 | Christian von Falck Gregor Beer Klaus F. Gratz Michael Galanski | 2007 | Clinical Nuclear Medicine2007，，： | 1 |
| 19 | Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches 显示文摘 | Galanski M Jakupec MA Keppler BK | 2005 | Curr Med Chem2005，12，18： | 1 |
| 20 | Renal arterial stenosis:helical CT angiography显示文摘 | Galanski M Prokop M Chavan A | 1993 | Radiology1993，189，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员